Chris Boshoff/LinkedIn
May 21, 2025, 13:17
Chris Boshoff: Pfizer Enters Licensing Agreement with 3SBio for Next-Gen Bispecific Antibody
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“I’m thrilled to share that Pfizer has entered into an exclusive licensing agreement with 3SBio Inc., focused on the global, ex-China, development and commercialization of a next-generation bispecific antibody targeting PD-1 and VEGF.
This innovative therapeutic is designed to target a range of malignancies, offering hope for improved treatment outcomes across difficult to treat solid tumors. Combining these mechanisms in a bispecific antibody creates a potential synergistic effect that may overcome resistance and enhance therapeutic efficacy.
This bispecific antibody is currently entering phase 3 clinical development in China, focusing on its potential in treating non-small cell lung cancer (NSCLC).
The development of next-generation therapies like the PD-1 and VEGF bispecific antibodies exemplify the latest innovation in Oncology, and holds promise for redefining standards of care in cancer treatment. The transaction is expected to close in the third quarter subject to the fulfillment of customary closing conditions. Stay tuned for further updates as we progress towards delivering impactful solutions in Oncology.”
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 13:04
May 21, 2025, 12:38
May 21, 2025, 12:32
May 21, 2025, 12:14
May 21, 2025, 12:07